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Abstract 
Many scientific efforts have been well done to investigate the effects of anti inflammatory agents on the degenerative 
brain diseases such as Parkinson’s (PD) or Alzheimer’s disease and their affiliated sings. Previously we showed the 
effectiveness of steroids on rigidity of PD and in the study for further mechanistic investigation of that observation the 
microdialysis technique was employed to determine the striatal dopamine changes in parkinsonian rats after 
administration of betamethasone (0.12, 0.24 mg/kg) respectively. Our findings showed us the significant increase in the 
striatal dopaminergic neurotransmission (P<0.05) after administration of betamethasone comparing to the controls. 
These observations suggest a new mechanism for betamethasone on striatum dopaminergic neurotransmission leading 
us to gather further evidence about effectiveness of betamethasone in PD. 
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Introduction 
 
Parkinson’s disease (PD) is a degenerative 
neurodopaminergic disease in the nigrostriatal 
pathway of humans/ animals, and the resultant losses 
of nerve terminals accompanied by dopamine 
deficiency in this pathway are responsible for most of 
the movement disorders. [1, 2] Increasing evidence 
suggests that an inflammatory reaction and 
pathological processes seen in many 
neurodegenerative disorders, including PD. [2] In cell 
culture and animal models, inflammation contributes 
to the neuronal damage and anti inflammatory agents 
such as dexamethasone has been shown to provide 
some neuroprotection or treatment of PD affiliated 
disorders such as rigidity by aspirin and 
betamethasone in animal model of PD. [3] In agreement 
the significant changes in the striatal 
neurotransmissions after the Cyclooxygenase-2 (COX-
2) as an important component of the inflammation[4]  
but not COX-1 selective inhibition were observed. 
These researches showed the significant increase in 
dopaminergic or decrease in gamma amino butyric 
acid (GABA)ergic-glutamatergic neurotransmissions 
after only selective COX-2 inhibition, coincidently the 
PD affiliated disorders significantly improved. [5-6] 
Notified researches intended to explore the important 
role for inflammation especially COX-2 in PD 
affiliated disorders and Striatum neurotransmissions. 
The study of striatal dopaminergic interactions has 
special importance due to the physiological and 
pathophysiological processes of these systems, such as 
Parkinson's or Alzheimer’s disease. [1, 2]   
The present work studies, assay of neurotransmitter 
dopamine concentration in the striatum of 
parkinsonian rats following administration of steroidal 
anti inflammatory drug betamethasone.  
Materials and Methods 
Animals 
Male albino Wistar rats were distributed into four 
groups that each group contained ten rats (200-250g). 
The animals were housed in stainless steel cages, 
handled daily, and provided food and water ad libitum. 
A 12h light/12-h dark cycle was maintained, and the 
animals were tested during the light cycle. These 
animal experiments were carried out in accordance 
with recommendations from the declaration of 
Helsinki and the internationally accepted principles in 
the use of experimental animals.   
Surgery 
Each rat was anesthetized separately by injection of 75 
mg/kg ketamine combined with 8 mg/kg Xylazin 
intraperitoneally (i.p.). Then we prepared the rats for 
surgery and placed them in the stereotaxic instrument.  
The left SNc [A/P -4.8 mm; M/L -1.6 mm and D/V 
+8.2 mm for left SNc according to the atlas [7]]  was 
destroyed using electrical lesion, 1 mA for 8 Sec [3] 
thus creating parkinsonian rats. Then the skull was 
exposed and a hole was drilled through it in the area 
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overlying the right striatum, using the following 
coordinates with respect to the bregma: A/P + 1 mm; 
M/L + 3 mm, D/V + 6 mm according to the atlas. [7] A 
guide-cannula lowered into the brain for inserting the 
microdialysis probe which delivered a modified 
Ringer solution through the probe, was fixed to the 
cranium and the incision was closed. Surgery was 
performed using sterile instruments and aseptic 
conditions. Rats were allowed to recover from the 
surgery for 7–10 days.  
Microdialysis procedure 
Betamethasone (0.12, 0.24 mg/kg) was administered 
i.p to parkinsonian rats and the microdialysate samples 
(20 µl) were collected every 20 min for 180 min after 
injection. Also control rats received saline injection (1 
ml/kg) i.p. Dopamine was analyzed by reverse-phase 
HPLC with electrochemical detection.  All samples 
were injected onto a reversed phase 5 µ C18 
250 mm × 4.6 mm column, which was protected by 
Krudkatcher disposable pre-column filters and 
SecurityGuard cartridges.  The mobile phase that was 
used on the ECD system was composed of a mixture 
of 0.11M di-sodium hydrogen orthophosphate/51 µM 
EDTA (pH 5.5, 1.1 M OPA) and HPLC grade 
methanol (32:61). The mobile phase was filtered 
through a Millipore 0.44 µm HV Durapore membrane 
filters and vacuum degassed prior to use. Dopamine 
concentrations were eluted isocratically over a 20 min 
runtime at a flow rate of 0.65 ml/min after a 20 µl 
injection. The column was maintained at a temperature 
of 30°C and samples/standards were kept at 4°C in the 
cooled autoinjector prior to analysis unless otherwise 
stated.  
 
 
Figure 1: Effects of Betamethasone (0.12, 0.24 mg/kg) on 
dopaminergic neurotransmission. All doses were observed to 
be enhanced significantly P<0.05 the striatal dopaminergic 
neurotransmission especially during within 40-180 min after 
betamethasone administration. 
Results 
The results showed the significant increase in amount 
of dopamine P<0.05 after administering the 
betamethasone (0.12, 0.24 mg/kg). The results are 
shown as the mean ± S.E.M. relative to the basal 
levels. The average concentration of three stable 
samples before drugs or vehicle [glycerin-acetone] 
administration was considered as the basal levels. 
These basal levels were taken as 100% in order to 
compare the different response of neurotransmitter 
after drug administration. Statistical evaluation of the 
results was performed by means of one-way analysis 
of variance (ANOVA) and Student–Newman–Keuls 
multiple range test, considering the following 
significant differences: p < 0.05. The striatal 
extraneuronal (i.e. microdialysate) levels of dopamine 
in SNc-lesioned rats of all examined groups before 
drug-vehicle injection (baseline) were 2.3±0.62 
pg/20µl, respectively. betamethasone (0.12, 0.24 
mg/kg) were observed to modify dopamine release in 
the striatum during within the observation period, as 
depicted in Figure 1. Statistically, the aforementioned 
changes were shown to be significant (p<0.05) for 
levels of dopamine on or after 20 min throughout until 
180 min (with the exception of betamethasone 
0.12mg/kg affected levels of dopamine which were 
significant only on or after 40min). Moreover 
Dopaminergic neurotransmission was enhanced 
33.82% [average of 40-180] after administration of 
betamethasone 0.12 mg/kg and 42.33% [average of 
40-180] after administration of betamethasone 0.24 
mg/kg comparing to the control groups.  
Discussion 
The study indicated the possibility of betamethasone 
to increase the release of dopamine in the striatal 
pathway, subsequently motivating the use of this agent 
to address improvements in brain degeneration such as 
PD, movement disorders effects as investigated 
previously [4, 8] The present study did not directly 
study improvements in movement disorders or the 
production of neuroprotective effects (our next area of 
investigation); at the same time, the present results 
hint at one possible mechanisms via which these 
effects can occur when steroidal anti inflammatory 
agents are used: increasing levels of striatal dopamine. 
It seems that inflammation and its mediators such as 
prostaglandins (PGs) have an important role in 
neurotransmitter release as noted in previous report,[8-
11] suggesting that inflammation causes increased 
levels of acetylcholine in the brain via production of 
PGE2 and increases in expression of cholinergic 
markers, such as choline acetyl transfrase and 
vesicular acetylcholine transporter protein. It was also 
noted that prostaglandins have modulatory effects on 
adrenergic, noradrenergic and glutaminergic 
transmission, specially PGE2,  and prostaglandin 
synthesis inhibitors induced increases in the blood 
pressure via increases in the release of the 
catecholamine; for example using large doses of 
glucocorticoids in humans may cause insomnia, 
euphoria and increase the intracranial pressure [8-11].  
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 Possible inflammatory components related to the PD 
and their exactly mode of actions should be elucidated 
by another future studies. Also it is necessary to 
clarify the role of steroidal anti inflammatory agents 
such as betamethasone on other striatal 
neurotransmissions. 
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